The role of adalimumab in rheumatic and autoimmune disorders

Comparison with other biologic agents

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with ADA. Long-term extension studies of some of the initial clinical trials, as well as data from large patient registries, are demonstrating ongoing benefit for responders. Potential side effects such as increased risk of infection, lymphoma, congestive heart failure, and demyelination continue to be examined, as the available data are not unanimous in showing an increase in incidence. In balancing both the advantages and the disadvantages of using ADA, the drug's overall effectiveness and its availability for use in patients with hepatic or renal co morbidities are weighed against the high cost. ADA is expected to have a leading role in the treatment of rheumatoid arthritis and other inflammatory conditions for years to come. Future studies will need to address the optimal sequence of disease-modifying antirheumatic drugs and biologics to use, combinations of disease-modifying antirheumatic drugs and biologics, and head-to-head comparisons of biologics in clinical trials. For those who go into clinical remission on an anti-tumor necrosis factor medication, unanswered questions remain about identifying the patients who can maintain the remission off all drugs, or at least off injected medication. Given the cost of biologic drugs, even studies that increase the interval between drug doses in well-controlled patients could provide financial benefits.

Original languageEnglish (US)
Pages (from-to)33-47
Number of pages15
JournalOpen Access Rheumatology: Research and Reviews
Volume4
StatePublished - May 3 2012

Fingerprint

Biological Factors
Biological Products
Antirheumatic Agents
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Clinical Trials
Pharmaceutical Preparations
Psoriatic Arthritis
Drug Costs
Juvenile Arthritis
Ankylosing Spondylitis
Demyelinating Diseases
United States Food and Drug Administration
Psoriasis
Crohn Disease
Registries
Lymphoma
Heart Failure
Adalimumab
Cytokines

Keywords

  • Disease-modifying antirheumatic drug
  • Humira®
  • Rheumatoid arthritis
  • Tumor necrosis factor alpha

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{66cf28db6dfa4b31871c293772201339,
title = "The role of adalimumab in rheumatic and autoimmune disorders: Comparison with other biologic agents",
abstract = "Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with ADA. Long-term extension studies of some of the initial clinical trials, as well as data from large patient registries, are demonstrating ongoing benefit for responders. Potential side effects such as increased risk of infection, lymphoma, congestive heart failure, and demyelination continue to be examined, as the available data are not unanimous in showing an increase in incidence. In balancing both the advantages and the disadvantages of using ADA, the drug's overall effectiveness and its availability for use in patients with hepatic or renal co morbidities are weighed against the high cost. ADA is expected to have a leading role in the treatment of rheumatoid arthritis and other inflammatory conditions for years to come. Future studies will need to address the optimal sequence of disease-modifying antirheumatic drugs and biologics to use, combinations of disease-modifying antirheumatic drugs and biologics, and head-to-head comparisons of biologics in clinical trials. For those who go into clinical remission on an anti-tumor necrosis factor medication, unanswered questions remain about identifying the patients who can maintain the remission off all drugs, or at least off injected medication. Given the cost of biologic drugs, even studies that increase the interval between drug doses in well-controlled patients could provide financial benefits.",
keywords = "Disease-modifying antirheumatic drug, Humira{\circledR}, Rheumatoid arthritis, Tumor necrosis factor alpha",
author = "Reimold, {Andreas M.}",
year = "2012",
month = "5",
day = "3",
language = "English (US)",
volume = "4",
pages = "33--47",
journal = "Open Access Rheumatology: Research and Reviews",
issn = "1179-156X",
publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - The role of adalimumab in rheumatic and autoimmune disorders

T2 - Comparison with other biologic agents

AU - Reimold, Andreas M.

PY - 2012/5/3

Y1 - 2012/5/3

N2 - Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with ADA. Long-term extension studies of some of the initial clinical trials, as well as data from large patient registries, are demonstrating ongoing benefit for responders. Potential side effects such as increased risk of infection, lymphoma, congestive heart failure, and demyelination continue to be examined, as the available data are not unanimous in showing an increase in incidence. In balancing both the advantages and the disadvantages of using ADA, the drug's overall effectiveness and its availability for use in patients with hepatic or renal co morbidities are weighed against the high cost. ADA is expected to have a leading role in the treatment of rheumatoid arthritis and other inflammatory conditions for years to come. Future studies will need to address the optimal sequence of disease-modifying antirheumatic drugs and biologics to use, combinations of disease-modifying antirheumatic drugs and biologics, and head-to-head comparisons of biologics in clinical trials. For those who go into clinical remission on an anti-tumor necrosis factor medication, unanswered questions remain about identifying the patients who can maintain the remission off all drugs, or at least off injected medication. Given the cost of biologic drugs, even studies that increase the interval between drug doses in well-controlled patients could provide financial benefits.

AB - Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with ADA. Long-term extension studies of some of the initial clinical trials, as well as data from large patient registries, are demonstrating ongoing benefit for responders. Potential side effects such as increased risk of infection, lymphoma, congestive heart failure, and demyelination continue to be examined, as the available data are not unanimous in showing an increase in incidence. In balancing both the advantages and the disadvantages of using ADA, the drug's overall effectiveness and its availability for use in patients with hepatic or renal co morbidities are weighed against the high cost. ADA is expected to have a leading role in the treatment of rheumatoid arthritis and other inflammatory conditions for years to come. Future studies will need to address the optimal sequence of disease-modifying antirheumatic drugs and biologics to use, combinations of disease-modifying antirheumatic drugs and biologics, and head-to-head comparisons of biologics in clinical trials. For those who go into clinical remission on an anti-tumor necrosis factor medication, unanswered questions remain about identifying the patients who can maintain the remission off all drugs, or at least off injected medication. Given the cost of biologic drugs, even studies that increase the interval between drug doses in well-controlled patients could provide financial benefits.

KW - Disease-modifying antirheumatic drug

KW - Humira®

KW - Rheumatoid arthritis

KW - Tumor necrosis factor alpha

UR - http://www.scopus.com/inward/record.url?scp=84864110781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864110781&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 33

EP - 47

JO - Open Access Rheumatology: Research and Reviews

JF - Open Access Rheumatology: Research and Reviews

SN - 1179-156X

ER -